| Literature DB >> 26106280 |
A Jaipal1, M M Pandey1, S Y Charde2, P P Raut1, K V Prasanth1, R G Prasad1.
Abstract
Delivery of orally compromised therapeutic drug molecules to the systemic circulation via buccal route has gained a significant interest in recent past. Bioadhesive polymers play a major role in designing such buccal dosage forms, as they help in adhesion of designed delivery system to mucosal membrane and also prolong release of drug from delivery system. In the present study, HPMC (release retarding polymer) and mannitol (diluent and pore former) were used to prepare bioadhesive and controlled release buccal discs of buspirone hydrochloride (BS) by direct compression method. Compatibility of BS with various excipients used during the study was assessed using DSC and FTIR techniques. Effect of mannitol and HPMC on drug release and bioadhesive strength was studied using a 3(2) factorial design. The drug release rate from delivery system decreased with increasing levels of HPMC in formulations. However, bioadhesive strength of formulations increased with increasing proportion of HPMC in buccal discs. Increased levels of mannitol resulted in faster rate of drug release and rapid in vitro uptake of water due to the formation of channels in the matrix. Pharmacokinetic studies of designed bioadhesive buccal discs in rabbits demonstrated a 10-fold increase in bioavailability in comparison with oral bioavailability of buspirone reported.Entities:
Keywords: Bioadhesion; Buccal; Buspirone hydrochloride; HPMC; Mannitol
Year: 2014 PMID: 26106280 PMCID: PMC4475836 DOI: 10.1016/j.jsps.2014.11.012
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Composition, drug content, thickness, friability and surface pH of the designed buccal discs.
| B. no | HPMC 15 K (mg) | Mannitol (mg) | MCC (mg) | Drug content (%) | Thickness (mm) | Friability (%) | Surface pH |
|---|---|---|---|---|---|---|---|
| F1 | 15.00 | 22.50 | 26.00 | 100.40 | 2.511 ± 0.010 | 0.27 | 6.86 ± 0.15 |
| F2 | 15.00 | 30.00 | 18.50 | 98.06 | 2.496 ± 0.006 | 0.53 | 6.91 ± 0.20 |
| F3 | 15.00 | 37.50 | 11.00 | 100.14 | 2.501 ± 0.017 | 0.13 | 7.01 ± 0.15 |
| F4 | 18.75 | 22.50 | 22.25 | 98.80 | 2.395 ± 0.021 | 0.60 | 6.86 ± 0.10 |
| F5 | 18.75 | 30.00 | 14.75 | 100.06 | 2.467 ± 0.015 | 0.33 | 7.03 ± 0.11 |
| F6 | 18.75 | 37.50 | 7.25 | 99.67 | 2.505 ± 0.010 | 0.73 | 6.59 ± 0.24 |
| F7 | 22.50 | 22.50 | 18.50 | 101.23 | 2.506 ± 0.011 | 0.27 | 7.16 ± 0.23 |
| F8 | 22.50 | 30.00 | 11.00 | 98.80 | 2.516 ± 0.006 | 0.27 | 6.94 ± 0.16 |
| F9 | 22.50 | 37.50 | 3.50 | 101.81 | 2.488 ± 0.020 | 0.40 | 7.02 ± 0.23 |
All the batches contain 10 mg BS and 1.50 mg of magnesium stearate.
Factors selected for 32 full factorial design along with levels and amounts of respective factors.
| Factors | Levels (mg) | ||
|---|---|---|---|
| −1 | 0 | +1 | |
| 15.00 | 18.75 | 22.50 | |
| 22.50 | 30.00 | 37.50 | |
Figure 1DSC thermogram obtained for pure drug BS (A), mannitol (B), BS and mannitol in 1:1 ratio (C), HPMC 15K (D), BS and HPMC 15K in 1:1 ratio (E), MCC (F) and BS with MCC in 1:1 ratio (G).
Figure 2FTIR spectrum obtained for pure drug, pure mannitol and physical mixture of BS-mannitol.
Figure 3Water uptake behavior of buccal discs (n = 3).
Coded factors, percent drug released at end of 5 h (Q5), time required to release 50% of drug (T50) and bioadhesive strength in Newton (FN) of the designed buccal discs.
| B. no | Coded factors | ||||
|---|---|---|---|---|---|
| Q5 (%) | T50 (h) | FN (N) | |||
| F1 | −1 | −1 | 82.69 | 1.58 | 9.57 |
| F2 | −1 | 0 | 86.31 | 1.53 | 9.47 |
| F3 | −1 | +1 | 99.59 | 1.39 | 9.61 |
| F4 | 0 | −1 | 79.02 | 1.76 | 10.39 |
| F5 | 0 | 0 | 82.30 | 1.59 | 10.13 |
| F6 | 0 | +1 | 93.40 | 1.25 | 9.89 |
| F7 | +1 | −1 | 69.95 | 2.62 | 12.00 |
| F8 | +1 | 0 | 73.20 | 2.29 | 12.14 |
| F9 | +1 | +1 | 79.15 | 2.18 | 11.97 |
Figure 4Predicted vs. actual and surface response plots of drug release at 5 H (Q5 in%), 50% drug release (T50 in h) and bioadhesion (FN in Newton) for the designed buccal discs.
Figure 5Drug release profile of designed buccal discs (n = 3).
Model fitting of in vitro drug release study for determination of mechanism and kinetics of drug release.
| B. no | Zero order | First order | Higuchi | Korsmeyer–Peppas | |
|---|---|---|---|---|---|
| ( | ( | ( | ( | ||
| F1 | 0.6846 | 0.9775 | 0.9535 | 0.9558 | 0.463 |
| F2 | 0.7154 | 0.9883 | 0.9577 | 0.9583 | 0.481 |
| F3 | 0.7235 | 0.9956 | 0.9713 | 0.9721 | 0.477 |
| F4 | 0.7587 | 0.9920 | 0.9814 | 0.9815 | 0.493 |
| F5 | 0.7455 | 0.9944 | 0.9780 | 0.9783 | 0.486 |
| F6 | 0.7326 | 0.9951 | 0.9745 | 0.9751 | 0.481 |
| F7 | 0.8381 | 0.9833 | 0.9907 | 0.9933 | 0.544 |
| F8 | 0.7782 | 0.9740 | 0.9872 | 0.9872 | 0.502 |
| F9 | 0.7610 | 0.9683 | 0.9858 | 0.9860 | 0.491 |
F∗, amount of drug dissolved at time t, ko, k1, kH, kp drug release rate constants of zero order, first order, Higuchi’s and Korsmeyer–Peppas model respectively.
“n” is dissolution exponent of Korsmeyer–Peppas model.
Figure 6Mean plasma concentration time profile of BS following intravenous and buccal (F3) administration (n = 3).
Pharmacokinetic parameters of BS when administered intravenously and via buccal route.
| Pharmacokinetic parameters | 10 mg BS solution (i.v) | 10 mg buccal disc (F3) |
|---|---|---|
| AUC0−∞ (ng h/mL) | 5153.90 ± 430.81 | 2129.57 ± 623.19 |
| – | 0.41 ± 0.09 | |
| 1384.68 ± 467.21 | 262.32 ± 43.29 | |
| – | 2.50 | |
| 2.53 ± 0.12 | 5.94 ± 0.37 |
Values are mean ± SD. n = 3.